Published in Am J Cardiol on June 27, 1986
The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med (1993) 4.61
Drug treatment of dyslipidemias: practical guidelines for the primary care physician. Heart Dis Stroke (1994) 2.68
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med (1967) 1.97
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther (2001) 1.65
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol (1998) 1.56
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med (1994) 1.46
The meetabolism of amiloride hydroloride in man. Clin Pharmacol Ther (1969) 1.33
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract (2003) 1.19
Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest (1971) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
Cadmium-binding proteins of rat testes. Characterization of a low-molecular-mass protein that lacks identity with metallothionein. Biochem J (1984) 1.04
L-dopa treatment failure: explanation and correction. Br Med J (1970) 0.95
Thyroglobulin structure-function. The amino acid sequence surrounding thyroxine. J Biol Chem (1983) 0.93
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol (1994) 0.92
Hog thyroid peroxidase: physical, chemical, and catalytic properties of the highly purified enzyme. Arch Biochem Biophys (1979) 0.90
Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med (1999) 0.89
Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med (1991) 0.88
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med (1987) 0.88
Toxicity of a hepatotoxic laxative preparation in tissue culture and excretion in bile in man. Clin Pharmacol Ther (1972) 0.86
Digoxin therapy during T-tube biliary drainage in man. JAMA (1978) 0.86
The instability of isoniazid and acetylisoniazid in frozen plasma. Res Commun Chem Pathol Pharmacol (1976) 0.86
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism (1993) 0.85
Drug interactions with fibric acids. Pharmacol Ther (1994) 0.85
L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro. Biochem Pharmacol (1971) 0.83
Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J Am Coll Nutr (1991) 0.83
Enterohepatic circulation of sulindac and metabolites. Clin Pharmacol Ther (1983) 0.83
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis (1986) 0.83
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis (2000) 0.82
Drug interactions of lipid-altering drugs. Drug Saf (1998) 0.82
Cadmium-binding proteins of rat testes. Apparent source of the protein of low molecular mass. Biochem J (1984) 0.82
Quantitation of biliary excretion of drugs in man. Clin Pharmacol Ther (1982) 0.82
Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin Pharmacol Ther (1980) 0.82
Methods to assess relative reliability of diet records: minimum records for monitoring lipid and caloric intake. J Am Diet Assoc (1986) 0.81
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol (2000) 0.81
Dual hepatic metabolism of cerivastatin--clarifications. Am J Cardiol (1999) 0.81
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial. Ann Intern Med (1988) 0.80
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
Low- vs high-dose aspirin. Effects on platelet function in hyperlipoproteinemic and normal subjects. Arch Intern Med (1986) 0.80
Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis (1988) 0.80
Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther (1990) 0.80
Serum lipids in normo- and hyperlipidemics after methyldopa and propranolol. Clin Pharmacol Ther (1984) 0.79
Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): studies in normal and hyperlipidemic subjects. J Cardiovasc Pharmacol (1997) 0.79
Experimental bases for the different hepatotoxicity of erythromycin preparations in man. J Lab Clin Med (1972) 0.79
Effect of diltiazem and low-dose aspirin on platelet aggregation and ATP release induced by paired agonists. Thromb Haemost (1993) 0.79
A clinical pharmacologist's view of drug hepatotoxicity. Pharmacol Res Commun (1977) 0.79
Hepatotoxicity of phenothiazines in vitro as measured by loss of aminotransferases to surrounding media. Proc Soc Exp Biol Med (1968) 0.79
Probucol. Curr Atheroscler Rep (2000) 0.78
Comparative clinical therapeutic trial with two hypolipidemic drugs: lofibrate and nafenopin. Clin Pharmacol Ther (1971) 0.78
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 0.78
The correlation of serum levels of two transaminases with tissue levels in six vertebrate species. Comp Biochem Physiol (1968) 0.78
Liver cell culture toxicity and surfactant potency of erythromycin derivatives. Toxicol Appl Pharmacol (1975) 0.78
Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparations. Biochem Pharmacol (1978) 0.78
The combined effects of N-3 fatty acids and aspirin on hemostatic parameters in man. Thromb Res (1990) 0.77
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol (1995) 0.77
Chlorpromazine uptake by isolated rat hepatocytes. Proc Soc Exp Biol Med (1979) 0.77
Thyroglobulin structure-function. Isolation and characterization of a thyroxine-containing polypeptide from bovine thyroglobulin. J Biol Chem (1981) 0.77
Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin Cardiol (2001) 0.76
Differences in iodinated peptides and thyroid hormone formation after chemical and thyroid peroxidase-catalyzed iodination of human thyroglobulin. Arch Biochem Biophys (1983) 0.76
Omega-3 fatty acids in hypertriglyceridemic patients: triglycerides vs methyl esters. Am J Clin Nutr (1988) 0.76
Cytotoxicity of phenothiazines on Chang liver cells as measured by enzyme leakage. Proc Soc Exp Biol Med (1969) 0.76
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis (1995) 0.76
One-year trials with halofenate, clofibrate, and placebo. Clin Pharmacol Ther (1976) 0.76
Hepatocyte responses to volatile anesthetics: changes in surface scanning and enzyme leakage. Anesth Analg (1979) 0.75
The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study. Am J Cardiol (1997) 0.75
Low-dose colestipol plus probucol for hypercholesterolemia. Am J Cardiol (1984) 0.75
Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority. Postgrad Med (1992) 0.75
The correlation between serum and tissue levels of enzymes in six vertebrate species--studies on lactate dehydrogenase, phosphohexose isomerase, aldolase and malate dehydrogenase. Comp Biochem Physiol (1969) 0.75
Tumors potentiating catecholamine-induced hypertension. Life Sci I (1971) 0.75
Colestipol and clofibrate in hypercholesterolemia. Clin Pharmacol Ther (1974) 0.75
Probucol with colestipol in the treatment of hypercholesterolemia. Ann Intern Med (1984) 0.75
Surface activity, cellular uptake and cytotoxicity of tricyclic psychoactive drugs in vitro. Biochem Pharmacol (1979) 0.75
Lipid-altering drugs in development. Drugs R D (1999) 0.75
One hundred digitalis blood levels. A utilization review. Eur J Clin Pharmacol (1979) 0.75
Calcium and CNS symptoms. N Engl J Med (1969) 0.75
Toxicity of hepatotoxic drugs on mouse liver tissue culture. Arch Int Pharmacodyn Ther (1970) 0.75
Comparison of two scoring systems used to monitor diets in outpatient clinical trials. J Cardiovasc Risk (1995) 0.75
Changes in liver and spleen scans of patients during treatment with two hypolipidemic drugs. Radiology (1971) 0.75
Alterations of liver-cell membranes after exposure to halothane. N Engl J Med (1980) 0.75
Erythromycin estolate vs. erythromycin base, surface excess properties and surface scanning changes in isolated liver cell systems. Pharmacology (1980) 0.75
Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients. Clin Pharmacol Ther (1970) 0.75
Elevated lipoprotein (a) blood levels as the single treatable atherosclerotic risk factor in patients with coronary artery disease. J Ky Med Assoc (1993) 0.75
Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. Prog Drug Res (1994) 0.75
Platelet function in hypercholesterolemics before and after hypolipidemic drug therapy. Haemostasis (1986) 0.75
Experimental investigations on the different hepatotoxic potential of erythromycin derivatives. Med Chir Dig (1976) 0.75
Interaction of mestranol with taurocholate uptake by isolated rat hepatocytes. Res Commun Chem Pathol Pharmacol (1979) 0.75
Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol (1984) 0.75
A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients. Am J Med Sci (1979) 0.75
Liver cell culture toxicity of general anesthetics. Toxicol Appl Pharmacol (1976) 0.75
The treatment of hyperlipoproteinemias. Ration Drug Ther (1979) 0.75
Hepatotoxicity and surface activity of tricyclic antidepressants in vitro. Toxicol Appl Pharmacol (1979) 0.75
Relationship between surface activity and toxicity to Chang liver cultures of tricyclic antidepressants. Pharmacology (1979) 0.75
Clinical trial design for obesity agents: a workshop report. Obes Res (1998) 0.75
Ethical, medical and legal issues for the use of placebos in future lipid intervention trials. Curr Opin Lipidol (2001) 0.75